Los efectos globo en los cultivos de coca en la región andina (1990-2009)

The aim of this article is to contrast empirically the presence of ballooneffects affecting coca crops in the geographic territory corresponding tothe main producer countries (Colombia, Perú and Bolivia) of the Andeanregion during the period 1990-2009. The empirical methodology has beenfocused in the specification and estimation of a simultaneous equation systemusing a SUR model. The model attempts to explain the behaviour ofthe number of hectares cultivated with coca plants as a function of differentvariables. We conclude that there is empirical evidence supporting the presenceof balloon effects in the Andean region during the period of inquiry.El objetivo de este artículo es poner a prueba estadísticamente la presencia de efectos globo en los cultivos de coca en el territorio geográfico correspondiente a los principales países productores en la región andina (Colombia, Perú y Bolivia) durante el periodo 1990-2009. La metodología empírica se centra en la especificación y estimación de un modelo de ecuaciones simultáneas utilizando el método SUR, el cual permite explicar el comportamiento de las hectáreas cultivadas con coca en función de un conjunto de determinantes. Se concluye que hay evidencia empírica a favor de la presencia de efectos globo en la región andina a lo largo del periodo estudiado

Desafíos en ciencia, tecnología e innovación en tiempo de Coronavirus Covid-19

El objetivo del presente estudio consistió en determinar el impacto de actividad física en la percepción de bienestar y salud en adolescentes, durante el periodo de confinamiento condicionado por la pandemia COVID-19. Se realizó un estudio observacional-longitudinal. N = 50 participantes (28 mujeres, 22 hombres; edad X = 15.12), quienes llevaron a cabo un programa de actividad física diseñado para espacios pequeños, además de realizar un pre y post-test. Los resultados muestran que hubo una mejora en la percepción de bienestar y salud después del periodo de actividad física (p=.05). Se concluye que, en la población de estudio, el programa de actividad física en espacios pequeños fue efectivo en la mejora de la percepción del bienestar y la salud

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

¿Se cumple la teoría neoclásica del comercio internacional?: el caso colombiano entre 1980 y 2007 [recurso electrónico]

El poder de predicción de la teoría neoclásica del comercio internacional ha sido muy cuestionado y debatido a lo largo de los siglos XX y XXI. Se retoma el debate en torno a la validez de la teoría neoclásica del comercio internacional y se concluye que no hay evidencia que permita refutar la teoría neoclásica del comercio internacional y, en particular, el teorema Heckscher-Ohlin, con el modelo gravitacional para el caso de la economía colombiana. A partir de una serie de datos anuales de comercio para Colombia entre los años 1980-2007 con estructura de panel, este trabajo encuentra que las dotaciones relativas de los factores relativamente abundantesde Colombia (trabajo y tierra) tienen un efecto positivo en los flujos comerciales. En consecuencia, se obtiene evidencia que apoya a la teoría neoclásica del comercio internacional para el caso colombiano

innovación tecnológica y comercio internacional : un análisis para los países de la comunidad andina de naciones : Bolivia, Colombia, Ecuador y Perú.

Maestría en Economía AplicadaEl presente artículo estudia la importancia del progreso tecnológico en el comercio exterior de los países de la CAN: Bolivia, Colombia, Ecuador y Perú. Se emplea un modelo gravitacional con estructura de panel para estimar el impacto de la innovación tecnológica sobre los flujos comerciales con datos anuales para el periodo 1980-2013. En general, los resultados indican que la capacidad de innovación no ejerce un efecto positivo y significativo sobre los flujos bilaterales, y en contraste, se observa la existencia de complementariedad en el comercio entre los países andinos y sus socios comerciales a pesar de las diferencias tecnológicas entre ellos

Se cumple la teoría neoclásica del comercio internacional? : el caso colombiano entre 1980 y 2007

PregradoECONOMIST

Los efectos globo en los cultivos de coca en la Región Andina (1990-2009)

El objetivo de este artículo es poner a prueba estadísticamente la presencia de efectos globo en los cultivos de coca en el territorio geográfico corres - pondiente a los principales países productores en la región andina (Colom - bia, Perú y Bolivia) durante el periodo 1990-2009. La metodología empíri - ca se centra en la especificación y estimación de un modelo de ecuaciones simultáneas utilizando el método SUR, el cual permite explicar el compor - tamiento de las hectáreas cultivadas con coca en función de un conjunto de determinantes. Se concluye que hay evidencia empírica a favor de la pre - sencia de efectos globo en la región andina a lo largo del periodo estudiado

Medical decisions concerning the end of life for cancer patients in three Colombian hospitals – a survey study

Background: Cancer patients’ end-of-life care may involve complex decision-making processes. Colombia has legislation regarding provision of and access to palliative care and is the only Latin American country with regulation regarding euthanasia. We describe medical end-of-life decision-making practices among cancer patients in three Colombian hospitals. Methods: Cancer patients who were at the end-of-life and attended in participating hospitals were identified. When these patients deceased, their attending physician was invited to participate. Attending physicians of 261 cancer patients (out of 348 identified) accepted the invitation and answered a questionnaire regarding end-of-life decisions: a.) decisions regarding the withdrawal or withholding of potentially life-prolonging medical treatments, b.) intensifying measures to alleviate pain or other symptoms with hastening of death as a potential side effect, and c.) the administration, supply or prescription of drugs with an explicit intention to hasten death. For each question addressing the first two decision types, we asked if the decision was fully or partially made with the intention or consideration that it may hasten the patient’s death. Results: Decisions to withdraw potentially life-prolonging treatment were made for 112 (43%) patients, 16 of them (14%) with an intention to hasten death. For 198 patients (76%) there had been some decision to not initiate potentially life-prolonging treatment. Twenty-three percent of patients received palliative sedation, 97% of all patients received opioids. Six patients (2%) explicitly requested to actively hasten their death, for two of them their wish was fulfilled. In another six patients, medications were used with the explicit intention to hasten death without their explicit request. In 44% (n = 114) of all cases, physicians did not know if their patient had any advance care directives, 26% (n = 38) of physicians had spoken to the patient regarding the possibility of certain treatment decisions to hasten death where this applied. Conclusions: Decisions concerning the end of life were common for patients with cancer in three Colombian hospitals, including euthanasia and palliative sedation. Physicians and patients often fail to communicate about advance care directives and potentially life-shortening effects of treatment decisions. Specific end-of-life procedures, patients’ wishes, and availability of palliative care should be further investigated.</p

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Data availability: Downloadable summary data are available through the GenOMICC data site (https://genomicc.org/data). Summary statistics are available, but without the 23andMe summary statistics, except for the 10,000 most significant hits, for which full summary statistics are available. The full GWAS summary statistics for the 23andMe discovery dataset will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. For further information and to apply for access to the data, see the 23andMe website (https://research.23andMe.com/dataset-access/). All individual-level genotype and whole-genome sequencing data (for both academic and commercial uses) can be accessed through the UKRI/HDR UK Outbreak Data Analysis Platform (https://odap.ac.uk). A restricted dataset for a subset of GenOMICC participants is also available through the Genomics England data service. Monocyte RNA-seq data are available under the title ‘Monocyte gene expression data’ within the Oxford University Research Archives (https://doi.org/10.5287/ora-ko7q2nq66). Sequencing data will be made freely available to organizations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research through a data access agreement. Sequencing data have been deposited at the European Genome–Phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001007111.Extended data figures and tables are available online at https://www.nature.com/articles/s41586-023-06034-3#Sec21 .Supplementary information is available online at https://www.nature.com/articles/s41586-023-06034-3#Sec22 .Code availability: Code to calculate the imputation of P values on the basis of SNPs in linkage disequilibrium is available at GitHub (https://github.com/baillielab/GenOMICC_GWAS).Acknowledgements: We thank the members of the Banco Nacional de ADN and the GRA@CE cohort group; and the research participants and employees of 23andMe for making this work possible. A full list of contributors who have provided data that were collated in the HGI project, including previous iterations, is available online (https://www.covid19hg.org/acknowledgements).Change history: 11 July 2023: A Correction to this paper has been published at: https://doi.org/10.1038/s41586-023-06383-z. -- In the version of this article initially published, the name of Ana Margarita Baldión-Elorza, of the SCOURGE Consortium, appeared incorrectly (as Ana María Baldion) and has now been amended in the HTML and PDF versions of the article.Copyright © The Author(s) 2023, Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown1 to be highly efficient for discovery of genetic associations2. Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group3. Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a strong focus on severe and critical disease: ISARIC4C (676 cases) and the SCOURGE consortium (5,934 cases). To put these results in the context of existing work, we conduct a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data. We find 49 genome-wide significant associations, of which 16 have not been reported previously. To investigate the therapeutic implications of these findings, we infer the structural consequences of protein-coding variants, and combine our GWAS results with gene expression data using a monocyte transcriptome-wide association study (TWAS) model, as well as gene and protein expression using Mendelian randomization. We identify potentially druggable targets in multiple systems, including inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).GenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome Trust Senior Research Fellowship (to J.K.B., 223164/Z/21/Z), the Department of Health and Social Care (DHSC), Illumina, LifeArc, the Medical Research Council, UKRI, a BBSRC Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and BBS/E/D/30002275) and UKRI grants MC_PC_20004, MC_PC_19025, MC_PC_1905 and MRNO2995X/1. A.D.B. acknowledges funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clinical Academic Track (ECAT) programme. This research is supported in part by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant MC_PC_20029). Laboratory work was funded by a Wellcome Intermediate Clinical Fellowship to B.F. (201488/Z/16/Z). We acknowledge the staff at NHS Digital, Public Health England and the Intensive Care National Audit and Research Centre who provided clinical data on the participants; and the National Institute for Healthcare Research Clinical Research Network (NIHR CRN) and the Chief Scientist’s Office (Scotland), who facilitate recruitment into research studies in NHS hospitals, and to the global ISARIC and InFACT consortia. GenOMICC genotype controls were obtained using UK Biobank Resource under project 788 funded by Roslin Institute Strategic Programme Grants from the BBSRC (BBS/E/D/10002070 and BBS/E/D/30002275) and Health Data Research UK (HDR-9004 and HDR-9003). UK Biobank data were used in the GSMR analyses presented here under project 66982. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government, British Heart Foundation and Diabetes UK. The work of L.K. was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). J.Y. is supported by the Westlake Education Foundation. SCOURGE is funded by the Instituto de Salud Carlos III (COV20_00622 to A.C., PI20/00876 to C.F.), European Union (ERDF) ‘A way of making Europe’, Fundación Amancio Ortega, Banco de Santander (to A.C.), Cabildo Insular de Tenerife (CGIEU0000219140 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.). We also acknowledge the contribution of the Centro National de Genotipado (CEGEN) and Centro de Supercomputación de Galicia (CESGA) for funding this project by providing supercomputing infrastructures. A.D.L. is a recipient of fellowships from the National Council for Scientific and Technological Development (CNPq)-Brazil (309173/2019-1 and 201527/2020-0)